HR3884FEDERALIN_COMMITTEE

Extension of Federal Sickle Cell Disease Research and Treatment Programs

Original title: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

September 24, 2024

healthcare public health medical research sickle cell disease federal funding

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced

Committee

Floor Vote

Passed

Signed

Currently IN_COMMITTEE. The next step in the legislative lifecycle is Floor Vote.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

The bill ensures the continuity of federal support for specialized blood disorder programs, which provide critical data collection and treatment resources for patients living with sickle cell disease and related conditions.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Patients with sickle cell disease and heritable blood disorders

The bill ensures the continued operation of federal research, surveillance, and treatment programs specifically targeting their conditions.

Public health agencies

These agencies maintain the legal authority to conduct research and surveillance programs for blood disorders through 2028.

What changed

Current stage: IN_COMMITTEE.

What's next

Floor Vote.

Summary

This bill extends federal funding and authorization for research, , and treatment programs for sickle cell disease and other inherited blood disorders for an additional five years. If passed, these programs will continue to operate through 2028.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

Frequently Asked Questions

What does this bill actually change?

It updates the expiration date for federal programs focused on sickle cell disease and other inherited blood disorders, extending their legal authorization from 2023 to 2028.

Does this bill provide new funding?

The bill s the existing program, which allows for the continued appropriation of funds for these specific health initiatives through 2028.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Lobbying Activity

INDIGO HILL STRATEGIES

on behalf of SICK CELLS

View filing →

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Five-Year Extension Pattern

The bill follows a standard five-year reauthorization cycle for public health programs, maintaining continuity for established research and surveillance infrastructure.

Public Health Service Act